Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e152e3ee12e8bcae8fe674cc9a811ff5 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-94 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-77 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-54 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6803 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6851 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
filingDate |
2021-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_297b6ee0f07cac572e12a047e5a71b5d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8cafe0fe5b6ba7cf8884e4873e232f0c |
publicationDate |
2022-05-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2022103811-A1 |
titleOfInvention |
Methods of treating axl-expressing cancers with anti-axl antibodies, antibody fragments and their immunoconjugates |
abstract |
Methods for treatment of Axl-expressing cancers are provided. The methods involve administering to a subject in need thereof, a polypeptide having a heavy chain variable region and/or light chain variable region that specifically binds to Axl protein, antibodies or antibody fragments containing the polypeptide, and/or an immunoconjugate compound thereof. The immunoconjugate compound is a Conditionally Active Biologic (CAB) anti-Axl antibody conjugated to one or more drug(s) via a cleavable linker (CAB-Axl-ADC). The immunoconjugate is a mAbBA3011-cleavable linker-MMAE (n) or pharmaceutically acceptable salt thereof, in which the mAbBA3011 is an antibody or antibody fragment, the MMAE is monomethyl auristatin E, and the (n) is an integer between 1 and 4. Pharmaceutical compositions and kits comprising the polypeptide or antibodies and antibody fragments containing the polypeptide are also provided. |
priorityDate |
2020-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |